The Federal Circuit upheld a ruling that Moderna’s COVID-19 vaccine does not infringe Alnylam’s mRNA patents related to the SM-102 lipid used in Spikevax.
Moderna Beats Alnylam Appeal In COVID Vaccine Patent Case
Where Today's News Shapes Tomorrow